Searchable abstracts of presentations at key conferences in endocrinology

ea0029p316 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Dysregulation of tissue renin–angiotensin–aldosterone system in obese hypertensive rats

Takeda Y. , Cheng Y. , Demura M. , Yoneda T. , Kometani M. , Sawamura T. , Karashima S.

The activation of local renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in the overall pathophysiology of the cardiovascular and renal diseases. Aldosterone can activate local renin and angiotensin converting enzyme (ACE). However, the effects of blockade of aldosterone on tissue RAAS including (pro)renin receptor and ACE2 are unclear in obese hypertensive rats induced by high-salt diet. Obese Zucker rats (ZOR) were fed with normal or high-salt diet ...

ea0029p35 | Adrenal cortex | ICEECE2012

Differential DNA methylation of the CYP11B1 and CYP11B2 genes in association with human adrenal zonation

Demura M. , Wang F. , Yoneda T. , Kometani M. , Sawamura T. , Cheng Y. , Ono K. , Nakamura Y. , Sasano H. , Saijoh K. , Takeda Y.

Background: The human adrenal cortex is composed of 3 distinct zones: the zona glomerulosa (ZG), the zona fasciculata (ZF), and the zona reticularis (ZR). Steroidogenic enzymes are expressed in a zone-specific manner. The promoters of CYP11B1 and CYP11B2 possess a number of target sites for DNA methylation that is closely associated with gene silencing.Methods and Materials: Adrenals from 5 autopsy subjects were assessed for immunohistrochemically define...

ea0029p33 | Adrenal cortex | ICEECE2012

Applicability of the guideline for the diagnosis of primary hyperaldosteronism in patients with hypertension in Japan (PHAS-J2): Prospective multi-center study of national hospital organization

Naruse M. , Miyazaki Y. , Tanaka T. , Shimizu M. , Otani S. , Hata S. , Ogo A. , Yonezawa K. , Yoshida K. , Sawamura M. , Araki R. , Tanabe M. , Tsuiki M. , Suzuki T. , Shimbo T.

Primary aldosteronism (PA) is the most major cause of secondary hypertension, with its prevalence ranging from 3 to 20% of the hypertensive patients. Although guideline for diagnosis of PA has been established by the Endocrine Society, details of its applicability remain to be elucidated. In this study, we investigated the applicability of each step of the guideline in hypertensive patients by the multi-center collaborative study of National Hospital Organization (NHO) in Japa...